These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 28823223)

  • 41. Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
    O'Day K; Meyer K; Stafkey-Mailey D; Watson C
    J Med Econ; 2015 Apr; 18(4):295-302. PubMed ID: 25422991
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Switching from natalizumab to an anti-CD20 monoclonal antibody in relapsing remitting multiple sclerosis: A systematic review.
    Brown JD; Muston BT; Massey J
    Mult Scler Relat Disord; 2024 Jun; 86():105605. PubMed ID: 38640586
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Natalizumab to fingolimod washout in patients at risk of PML: when good intentions yield bad outcomes.
    Giovannoni G; Naismith RT
    Neurology; 2014 Apr; 82(14):1196-7. PubMed ID: 24610331
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.
    Frau J; Saccà F; Signori A; Baroncini D; Fenu G; Annovazzi P; Capobianco M; Signoriello E; Laroni A; La Gioia S; Sartori A; Maniscalco GT; Bonavita S; Clerico M; Russo CV; Gallo A; Lapucci C; Carotenuto A; Sormani MP; Cocco E;
    J Neurol; 2019 Oct; 266(10):2440-2446. PubMed ID: 31209573
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation.
    González-Suarez I; Rodríguez de Antonio L; Orviz A; Moreno-García S; Valle-Arcos MD; Matias-Guiu JA; Valencia C; Jorquera Moya M; Oreja-Guevara C
    Brain Behav; 2017 Apr; 7(4):e00671. PubMed ID: 28413713
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Annualized hospitalization rate with natalizumab vs fingolimod in second-line treatment for RRMS in the public healthcare system in Brazil: A claim database approach.
    Julian GS; Rosim RP; Carneseca EC; Rigolon J
    PLoS One; 2020; 15(3):e0229768. PubMed ID: 32119696
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Real-life clinical use of natalizumab and fingolimod in Austria.
    Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T
    Acta Neurol Scand; 2018 Feb; 137(2):181-187. PubMed ID: 29159801
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
    Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
    BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).
    Clerico M; Schiavetti I; De Mercanti SF; Piazza F; Gned D; Brescia Morra V; Lanzillo R; Ghezzi A; Bianchi A; Salemi G; Realmuto S; Sola P; Vitetta F; Cavalla P; Paolicelli D; Trojano M; Sormani MP; Durelli L
    JAMA Neurol; 2014 Aug; 71(8):954-60. PubMed ID: 24977406
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
    Campbell JD; McQueen RB; Miravalle A; Corboy JR; Vollmer TL; Nair K
    Am J Manag Care; 2013 Apr; 19(4):278-85. PubMed ID: 23725360
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
    Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High cumulative JC virus seroconversion rate during long-term use of natalizumab.
    Vennegoor A; van Rossum JA; Leurs C; Wattjes MP; Rispens T; Murk JL; Uitdehaag BM; Killestein J
    Eur J Neurol; 2016 Jun; 23(6):1079-85. PubMed ID: 27018481
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recurrence of disease activity after repeated Natalizumab withdrawals.
    Ferrè L; Moiola L; Sangalli F; Radaelli M; Barcella V; Comi G; Martinelli V
    Neurol Sci; 2015 Mar; 36(3):465-7. PubMed ID: 25249399
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab.
    Fissolo N; Pignolet B; Rio J; Vermersch P; Ruet A; deSèze J; Labauge P; Vukusic S; Papeix C; Martinez-Almoyna L; Tourbah A; Clavelou P; Moreau T; Pelletier J; Lebrun-Frenay C; Bourre B; Defer G; Montalban X; Brassat D; Comabella M
    Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 33903203
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and Efficacy of Fingolimod and Natalizumab in Multiple Sclerosis After the Failure of First-Line Therapy: Single Center Experience Based on the Treatment of Forty-Four Patients.
    Puz P; Lasek-Bal A
    Med Sci Monit; 2016 Nov; 22():4277-4282. PubMed ID: 27829656
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice].
    Alcala-Vicente C; Perez-Miralles FC; Gascon-Gimenez F; Bosca-Blasco I; Navarre-Gimeno A; Coret-Ferrer F; Casanova-Estruch B
    Rev Neurol; 2017 May; 64(10):445-453. PubMed ID: 28497440
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in Iran.
    Rezaee M; Izadi S; Keshavarz K; Borhanihaghighi A; Ravangard R
    J Med Econ; 2019 Apr; 22(4):297-305. PubMed ID: 30561242
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Update on disease-modifying therapies for multiple sclerosis.
    Vargas DL; Tyor WR
    J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Natalizumab extended interval dosing: what about wearing-off effect?
    Bernardes C; Fernandes C; Cunha C; Nunes C; Macário C; Sousa L; Batista S; Correia I
    J Neurol Sci; 2024 Mar; 458():122930. PubMed ID: 38368641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.